<?xml version="1.0" encoding="UTF-8"?>
<p>To outline and implement clinical trials pilot projects, a considerable amount of funding and expertise especially on unique medical conditions are always important abut can be difficult to obtain for specific projects required by biotechnology and pharmaceutical industries. Nonetheless, out-licensing may address this hurdle contingent upon the eagerness of small biotech companies or research organisations to take up the aforementioned risk, which, to date, is limited [
 <xref rid="B112-viruses-12-01058" ref-type="bibr">112</xref>]. 
</p>
